Ftse Mib
34.474,26
0,04%
DAX
18.701,70
0,10%
S&P 500
5.307,01
-0,27%
NASDAQ
16.801,54
-0,18%
Bitcoin
69.613,88
0,74%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ TriSalus Life Sciences Inc (TLSI) TriSalus Life Sciences Inc (TLSI) Notizie

TLSI

TriSalus Life Sciences (TLSI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TLSI
DataOraFonteTitoloSimboloCompagnia
15/05/202414:00Business WireTriSalus Reports Q1 2024 Financial Results and Business UpdateNASDAQ:TLSITriSalus Life Sciences Inc
07/05/202413:00Business WireTriSalus Life Sciences Appoints Liselotte Hyveled to its Board of DirectorsNASDAQ:TLSITriSalus Life Sciences Inc
06/05/202422:58Business WireTriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference CallNASDAQ:TLSITriSalus Life Sciences Inc
30/04/202422:35Business WireTriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth InitiativesNASDAQ:TLSITriSalus Life Sciences Inc
01/04/202414:00Business WireTriSalus Reports Q4 and Full Year 2023 Financial Results and Business UpdateNASDAQ:TLSITriSalus Life Sciences Inc
26/03/202413:00Business WireTriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific MeetingNASDAQ:TLSITriSalus Life Sciences Inc
21/03/202413:00Business WireTriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific MeetingNASDAQ:TLSITriSalus Life Sciences Inc
11/03/202422:15Business WireTriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial ResultsNASDAQ:TLSITriSalus Life Sciences Inc
07/03/202413:00Business WireTriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101NASDAQ:TLSITriSalus Life Sciences Inc
29/02/202413:00Business WireTriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver TumorsNASDAQ:TLSITriSalus Life Sciences Inc
15/02/202400:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TLSITriSalus Life Sciences Inc
25/01/202423:23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TLSITriSalus Life Sciences Inc
25/01/202423:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TLSITriSalus Life Sciences Inc
27/12/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TLSITriSalus Life Sciences Inc
14/11/202314:00Business WireTriSalus Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TLSITriSalus Life Sciences Inc
07/11/202322:05Business WireTriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference CallNASDAQ:TLSITriSalus Life Sciences Inc
04/11/202319:25Business WireLate-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas IndicationsNASDAQ:TLSITriSalus Life Sciences Inc
03/11/202317:00Business WireTriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:TLSITriSalus Life Sciences Inc
25/10/202315:05Business WireTriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNASDAQ:TLSITriSalus Life Sciences Inc
19/10/202303:58Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:TLSITriSalus Life Sciences Inc
16/10/202323:23Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TLSITriSalus Life Sciences Inc
06/09/202313:00Business WireTriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus TherapeuticsNASDAQ:TLSITriSalus Life Sciences Inc
01/09/202303:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TLSITriSalus Life Sciences Inc
31/08/202323:22Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:TLSITriSalus Life Sciences Inc
29/08/202314:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TLSITriSalus Life Sciences Inc
21/08/202322:33Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:TLSITriSalus Life Sciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TLSI

La tua Cronologia

NASDAQ
CRVL
CorVel
EU
F320T
F320T
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network